Genmab A/S
GMAB · NASDAQ
Bulios Fair Price
$45.04
37.9% upside
Trenutna cena
$32.65
Po podatkih Bulios Fair Price je delnica GMAB trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Genmab A/S (GMAB) is a Danish biotechnology company specializing in the research, development, and manufacturing of monoclonal antibodies for the treatment of various types of cancer and immune-related diseases. The company is known for its innovative approaches to therapies and a robust portfolio of therapeutic antibodies undergoing clinical trials. Genmab focuses on collaborations with pharmaceutical partners and leverages its advanced technology to create medicines with the potential to revolutionize the way diseases are treated. Genmab A/S (GMAB) shares might appeal to investors seeking exponential growth in the biotechnology sector.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Jan van de Winkel
Employees
3,119
Headquarters
Copenhagen
Prihajajoči dogodki
Earnings
Upcoming earnings report